The tweet was deleted by the author.
But we saved everything 🙂.
Myriad Genetics has introduced its MyRisk Hereditary Cancer Test designed to provide clear, guideline-aligned recommendations in managing lifelong colorectal cancer (CRC) care.
The test aims to support both patients and their families by informing decisions on surveillance intensity, second cancer screening, and specialty care post-surgery. The initiative targets ongoing CRC patient management, not just surgical outcomes, seeking to optimize preventive strategies and improve quality of care.
The company recently launched an AI enhanced test for active surveillance, focusing on improved management in urology and prostate cancer care. Myriad is also set to roll out the Prolaris plus AI Test, which combines molecular scores with digital pathology for prostate cancer diagnosis. These moves expand Myriad Genetics’ portfolio of risk assessment tools across cancer indications.